We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Idiopathic Pulmonary Fibrosis patients' COVID-19 quarantine; not just a routine.
- Authors
Dimeas, Ilias E.; Sinis, Sotirios I.; Kotsiou, Ourania S.; Daniil, Zoe
- Abstract
Amidst the Corona Virus Disease 19 [COVID-19] pandemic we have been receiving an increasing amount of open-hearted concerns from Idiopathic Pulmonary Fibrosis (IPF) patients regarding the unraveling global tragedy through phone call appointments, which have replaced outpatient visits during the national lockdown1. Upon reflecting on their sincere thoughts one can sympathize with the predicament IPF patients are currently encountering, which is highly unrecognized because of global turmoil and the fact that this population is in many aspects (research, public awareness, media coverage...) underrepresented. Therefore, we decided to provide insights into the COVID-19 calamity from an IPF patient point of view, drawing inspiration from our patient's confessions. IPF remains a rapidly progressive disease with poor prognosis. It wasn't until recently that disease modifying drugs, pirfenidone and nintedanib, were approved heralding a new era in the treatment of IPF. Prior to this benchmark event, patients had no choice but to come to terms with the fact that there is no treatment proven effective in slowing pulmonary function deterioration2. Currently, they find themselves placed within a population susceptible to a novel disease that yet again lacks evidence-based therapeutic interventions.
- Publication
Pneumon, 2020, Vol 33, Issue 2, p56
- ISSN
1105-848X
- Publication type
Academic Journal